Research Article
The Prognostic Significance of HALP Index for Colon Cancer Patients in a Hispanic-Based Population
Table 1
General characteristics of patients.
| | Variables | Total (n = 640) | HALP | value | | <15.0 | ≥15.0 |
| | Age group, n (%) | | | | 0.974 | | <40 | 91 (14.2) | 67 (14.0) | 24 (14.7) | | | 40–70 | 424 (66.3) | 317 (66.5) | 107 (65.6) | | | >70 | 125 (19.5) | 93 (19.5) | 32 (19.6) | |
| | Gender, n (%) | | | | 0.482 | | Female | 319 (49.8) | 237 (49.7) | 82 (50.3) | | | Male | 321 (50.2) | 240 (50.3) | 81 (49.7) | |
| | BMI in kg/m2, n (%) | | | | <0.001 | | <18.5 | 24 (3.8) | 15 (3.1) | 9 (5.5) | | | 18.5–24.9 | 315 (49.2) | 216 (45.3) | 99 (60.7) | | | 25–29.9 | 206 (32.2) | 163 (34.2) | 43 (26.4) | | | ≥30 | 95 (14.8) | 83 (17.4) | 12 (7.4) | |
| | pTNM stage, n (%) | | | | 0.02 | | I | 75 (11.7) | 8 (4.9) | 67 (14.0) | | | II | 276 (43.1) | 84 (51.5) | 192 (40.3) | | | III | 289 (45.2) | 71 (43.6) | 218 (45.7) | |
| | Tumor differentiation, n (%) | | | | 0.006 | | Well | 121(18.9) | 96 (20.1) | 25 (15.3) | | | Moderate | 362 (56.6) | 279 (58.5) | 83 (50.9) | | | Poor | 157 (24.5) | 102 (21.4) | 55 (33.7) | |
| | Tumor location, n (%) | | | | <0.001 | | Right colon | 322 (50.3) | 205 (43.0) | 117 (71.8) | | | Left colon | 318 (49.7) | 272 (57.0) | 46 (28.2) | |
| | Lymphovascular invasion, n (%) | | | | 0.183 | | No | 421 (65.8) | 319 (66.9) | 102 (62.6) | | | Yes | 219 (34.2) | 158 (33.1) | 61 (37.4) | |
| | Perineural invasion, n (%) | | | | 0.385 | | No | 523 (87.1) | 388 (81.3) | 135 (82.8) | | | Yes | 117 (18.3) | 89 (18.7) | 28 (17.2) | |
| | Number of resected lymph nodes, n (%) | | | | <0.001 | | <12 | 95 (14.8) | 85 (17.8) | 10 (6.1) | | | ≥12 | 545 (85.2) | 392 (82.2) | 153 (93.9) | |
| | Pathology T stage, n (%) | | | | <0.001 | | T1 | 22 (3.4) | 19 (4) | 3 (1.8) | | | T2 | 69 (10.8) | 2 (13.4) | 5 (3.1) | | | T3 | 380 (59.4) | 290 (60.8) | 90 (55.2) | | | T4 | 169 (26.4) | 104 (21.8) | 65 (39.9) | |
| | Pathology N stage, n (%) | | | | 0.372 | | N0 | 357 (55.8) | 263 (55.1) | 94 (57.7) | | | N1 | 164 (25.6) | 119 (24.9) | 45 (25.6) | | | N2 | 119 (18.6) | 95 (19.9) | 24 (14.7) | |
| | Surgical margins/type of resection, n (%) | | | | 0.589 | | R0 | 626 (97.8) | 465 (97.5) | 161 (98.8) | | | R1 | 13 (2.0) | 11 (2.3) | 2 (1.2) | | | R2 | 1 (0.2) | 1 (1.2) | 0 | |
| | Cancer obstruction, n (%) | | | | 0.424 | | No | 562 (87.8) | 420 (88.1) | 142 (87.1) | | | Yes | 78 (12.2) | 57 (11.9) | 21 (12.9) | |
| | Cancer perforation, n (%) | | | | 0.170 | | No | 583 (91.1) | 438 (91.8) | 145 (89) | | | Yes | 57 (8.9) | 39 (8.2) | 18 (11) | |
| | CCI, n (%) | | | | 0.377 | | 0 | 180 (21.8) | 126 (26.4) | 54 (33.1) | | | 1 | 152 (23.8) | 118 (24.7) | 34 (20.9) | | | 2 | 129 (20.2) | 96 (20.1) | 33 (20.2) | | | ≥3 | 179 (28.0) | 137 (28.7) | 42 (25.8) | |
| | Postoperative complications, n (%) | | | | 0.227 | | No | 551 (86.1) | 414 (86.8) | 137 (84) | | | Yes | 89 (13.9) | 63 (13.2) | 26 (16) | |
| | Adjuvant chemotherapy, n (%) | | | | 0.146 | | No | 244 (38.1) | 188 (39.4) | 56 (34.4) | | | Yes | 396 (61.9) | 289 (60.6) | 107 (65.6) | |
|
|
HALP: hemoglobin (g/L) × albumin (g/L) × lymphocytes (/L)/platelets (/L), BMI: body mass index, pTNM: pathological tumor-node-metastasis stage, CCI: Charlson comorbidity index.
|
